Vaccinating against GD3 ganglioside using BEC2 anti-idiotypic monoclonal antibody. Review uri icon

Overview

abstract

  • GD3, a ganglioside expressed on tumors of neuroectodermal origin such as melanoma and small-cell lung carcinoma (SCLC), is an attractive vaccine target but is poorly immunogenic. Our group has pursued several strategies designed to immunize patients against GD3 including using BEC2, an anti-idiotypic monoclonal antibody that mimics GD3. Pilot trials in melanoma and SCLC indicate that BEC2 can induce an anti-GD3 antibody response in a subset of patients and also suggests that immunization with BEC2 is associated with improved survival. A phase III trial is underway in SCLC patients to determine the effects of BEC2 on overall survival.

publication date

  • June 1, 2003

Research

keywords

  • Antibodies, Anti-Idiotypic
  • Gangliosides
  • Immunotherapy, Active
  • Potassium Channels, Voltage-Gated

Identity

Scopus Document Identifier

  • 0041664883

PubMed ID

  • 12901230

Additional Document Info

volume

  • 4

issue

  • 6